The Davis Companies secured a full-building lease agreement at 100 Technology Way in Smithfield, RI, an approximately 123,000-square-foot biomanufacturing facility, with Organogenesis Holdings Inc., a leading regenerative medicine company. Lease terms were not disclosed.

“In a competitive manufacturing and life sciences market, our lease agreement with Organogenesis demonstrates Davis’ commitment to providing premier tenant experiences in locations that best allow businesses to innovate and scale,” said Davis SVP of asset management Jon Needham. “We are thrilled to welcome Organogenesis to the building and to support their growth plans as the company leads in the biomanufacturing sector and enhances Rhode Island’s and greater New England’s innovation ecosystem.”

A multi-year construction project is now underway to enhance 100 Technology Way’s existing capabilities as a cGMP facility. The building is fed by a significant utility infrastructure which will support Organogenesis’ manufacturing uses.

Organogenesis was represented by Robert Coughlin and Bobby Jangro of JLL. Mark Winters and Tyler McGrail of Newmark represented Davis and the property.